| Literature DB >> 35719763 |
Michael Sindos1, Konstantinos Kalmantis1, Konstantinos Samartzis1, Michail Diakosavvas1, Andreas Kalampalikis1, Konstantina Kalopita2, Emmanouil Stamatakis2, Dimitrios Valsamidis2, George Daskalakis1.
Abstract
Background Although peripartum hysterectomy (PH) is a life-saving procedure in cases of abnormal placentation and postpartum hemorrhage, it can be associated with major obstetric and anesthetic complications. This retrospective study aimed to evaluate the incidence, etiology, perioperative anesthetic and obstetric management, complications, and fetal outcomes in women undergoing PH in a single tertiary referral hospital in Greece. Methodology This was a retrospective analysis of medical records of women who underwent emergency or elective PH in our hospital between January 2015 and December 2018. Results During the study period, 69 women who underwent a PH were identified. The incidence rate of elective and emergency PH was 4 and 1.2 per 1,000 deliveries, respectively. The main indication for PH was abnormal placentation (81.2%), followed by uterine atony (13%). Conversion to general anesthesia (GA) was performed in 21 (30.4%) cases. Conclusions This study showed a high prevalence of PH in our hospital compared to high-income countries. A neuraxial-only technique may be a safe alternative in individual cases of abnormal placentation. Conversion to GA can be reserved for complex surgical cases when massive hemorrhage is anticipated and, if possible, after the neonate has been delivered.Entities:
Keywords: abnormal placentation; abnormally invasive placenta; peripartum hysterectomy; placenta accreta spectrum disorder; postpartum hemorrhage; uterine atony
Year: 2022 PMID: 35719763 PMCID: PMC9201674 DOI: 10.7759/cureus.25062
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Maternal and clinical characteristics of cases.
SD: standard deviation; IQR: interquartile range; BMI: body mass index; RBC: red blood cell; FFP: fresh frozen plasma; PLT: platelet; PCC: prothrombin complex concentrate; ICU: intensive care unit; HDU: high dependency unit
| Age, mean (SD) | 34.9 (5.6) | |
| BMI, mean (SD) | 28.4 (5.1) | |
| Gestational age (weeks), mean (SD) | 35 (2.4) | |
| Parity, N (%) | 1 | 3 (4.3) |
| 2 | 26 (37.7) | |
| 3 | 20 (29.0) | |
| >3 | 20 (29.0) | |
| Previous cesarean section, N (%) | 0 | 8 (11.6) |
| 1 | 27 (39.1) | |
| 2 | 19 (27.5) | |
| >2 | 15 (21.7) | |
| Indications for peripartum hysterectomy, N (%) | Placenta accreta | 7 (10.1) |
| Placenta increta | 31 (44.9) | |
| Placenta percreta | 18 (26.1) | |
| Uterine atony | 9 (13.0) | |
| Uterine rupture | 1 (1.4) | |
| Ovarian cancer | 1 (1.4) | |
| Uterine sarcoma | 1 (1.4) | |
| History of trachelectomy (cervical cancer) | 1 (1.4) | |
| Intraoperative blood loss (mL), median (IQR) | 3,771 (500–9,400) | |
| Preoperative hemoglobin (g/dL), mean (SD) | 9.3 (1.6) | |
| Postoperative hemoglobin reduction (g/dL), mean (SD) | 0.5 (1.8) | |
| Intraoperative crystalloid fluids transfused, mean (SD) | 3,792.3 (1,198.3) | |
| Units of RBCs transfused, median (IQR) | 4 (2–5) | |
| Units of FFP transfused, median (IQR) | 3 (2–4) | |
| PLTs transfusion, N (%) | 2 (2.9) | |
| PCCs administration, N (%) | 2 (2.9) | |
| Tranexamic acid administration, N (%) | 33 (47.8) | |
| Fibrinogen administration, N (%) | 14 (20.3) | |
| Emergency cesarean section, N (%) | 19 (27.5) | |
| Gynecological oncologist in addition to obstetrician, N (%) | 42 (60.9) | |
| Urologist in addition to obstetrician, N (%) | 6 (8.7) | |
| Admission to the ICU, N (%) | 4 (5.8) | |
| Admission to the HDU, N (%) | 66 (95.7) | |
| Routine postpartum bed, N (%) | 0 (0.0) | |
| Duration of hospital stay (days), median (IQR) | 10 (8–19) | |
| Duration of postoperative hospital stay (days), median (IQR) | 7 (6–9) | |
Anesthetic data.
CSE: combined spinal-epidural; GA: general anesthesia; RBC: red blood cell; NSAIDs: non-steroidal anti-inflammatory drugs; COX-2: cyclooxygenase-2; PCA: patient-controlled analgesia; IV: intravenous
| Type of anesthesia | N (%) | |
| Neuraxial | 28 (40.6) | |
| CSE | 20 (29.0) | |
| CSE + top-up epidural | 1 (1.4) | |
| Double-space CSE | 2 (2.9) | |
| Epidural | 2 (2.9) | |
| Spinal | 3 (4.3) | |
| Conversion to GA | 21 (30.4) | |
| GA | 41 (59.4) | |
| Induction to GA | N (%) | |
| Etomidate | 1 (1.4) | |
| Propofol | 16 (23.2) | |
| Thiopental | 41 (59.4) | |
| Intubation | N (%) | |
| Videolaryngoscope | 1 (1.4) | |
| Direct endotracheal intubation | 62 (89.9) | |
| Maintenance of anesthesia | N (%) | |
| Desflurane | 1 (1.4) | |
| Propofol | 2 (2.9) | |
| Sevoflurane | 59 (85.5) | |
| Opioids | N (%) | |
| Fentanyl boluses | 54 (78.3) | |
| Morphine-fentanyl boluses | 7 (10.1) | |
| Reported anesthetic complications | N (%) | |
| No complications | 67 (97.1) | |
| Bronchospasm | 1 (1.4) | |
| Allergic reaction after RBC transfusion | 1 (1.4) | |
| Remaining intraoperative anesthetic data | N (%) | |
| Extubated at the end of the case | 60 (87.0) | |
| Vasoactive drugs | 12 (17.4) | |
| Invasive blood pressure monitoring | 60 (87.0) | |
| Internal jugular venous access | 20 (29.0) | |
| Postoperative analgesia | N (%) | |
| Epidural morphine ± ropivacaine 0.2%+ IV paracetamol + conventional NSAIDs/COX-2 inhibitorsv ± IV opioids | 9 (13.0) | |
| Epidural morphine + IV PCA | 37 (53.6) | |
| IV paracetamol + conventional NSAIDs/COX-2 inhibitors + IV PCA | 9 (13.0) | |
| IV paracetamol + conventional NSAIDs/COX-2 inhibitors + IV strong opioids | 13 (18.8) | |
| IV paracetamol + conventional NSAIDs/COX-2 inhibitors + IV weak opioids | 5 (7.2) | |
Association of RBC, FFP, tranexamic acid, and fibrinogen administration with clinical data.
RBC-FFP transfusions: +Kruskal-Wallis test; ++Mann-Whitney test; ‡Spearman’s correlation coefficient.
Tranexamic acid-fibrinogen administration: +Student’s t-test; ++Mann-Whitney test; ‡Pearson’s chi-square test; ‡‡Fisher’s exact test.
IQR: interquartile range; RBC: red blood cell; FFP: fresh frozen plasma; BMI: body mass index
| RBC transfusions | FFP transfusions | Tranexamic acid | Fibrinogen | ||||||||
| Median (IQR) | P-value | Median (IQR) | P-value | No, N (%) | Yes, N (%) | P-value | No, N (%) | Yes, N (%) | P-value | ||
| Age, r‡ | -0.17 | 0.154 | -0.08 | 0.481 | 35 (5.5) | 35.4 (5.7) | 0.735+ | 35.2 (5.8) | 34.8 (4.1) | 0.786+ | |
| BMI, r‡ | -0.11 | 0.441 | -0.15 | 0.297 | 28.7 (5.2) | 27.4 (4.7) | 0.385+ | 27.8 (4.6) | 29.7 (6.5) | 0.273+ | |
| Parity | 1-2 | 4 (2–5) | 0.482+ | 3 (2–4) | 0.978+ | 18 (56.3) | 14 (43.8) | 0.962‡ | 27 (84.4) | 5 (15.6) | 0.518‡‡ |
| 3 | 4 (2–6) | 3 (2–4) | 11 (52.4) | 10 (47.6) | 15 (71.4) | 6 (28.6) | |||||
| >3 | 4 (3–5) | 2 (2–4) | 11 (55.0) | 9 (45.0) | 17 (85.0) | 3 (15.0) | |||||
| Gestational age (weeks), r‡ | -0.10 | 0.409 | 0.03 | 0.771 | 34.3 (3.4) | 34 (4.8) | 0.776+ | 34.3 (3.6) | 33.5 (5.6) | 0.530+ | |
| Previous cesarean section | 0 | 2.5 (2–5) | 0.423+ | 2 (2–4) | 0.903+ | 5 (50.0) | 5 (50.0) | 0.865‡ | 7 (70.0) | 3 (30.0) | 0.680‡‡ |
| 1 | 4 (2–5) | 3 (2–4.5) | 14 (50.0) | 14 (50.0) | 24 (85.7) | 4 (14.3) | |||||
| 2 | 4 (2–6) | 3 (2–4) | 12 (60.0) | 8 (40.0) | 16 (80.0) | 4 (20.0) | |||||
| >2 | 4 (3–5) | 2 (2–4) | 9 (60.0) | 6 (40.0) | 12 (80.0) | 3 (20.0) | |||||
| Emergency cesarean section | No | 4 (2–5) | 0.379++ | 2 (2–4) | 0.007++ | 29 (58.0) | 21 (42.0) | 0.529‡ | 42 (84.0) | 8 (16.0) | 0.335‡‡ |
| Yes | 4 (2–5) | 4 (2–5) | 11 (50.0) | 11 (50.0) | 16 (72.7) | 6 (27.3) | |||||
| Duration of hospital stay (days), r‡ | 0.09 | 0.486 | 0.04 | 0.765 | 13.5 (8–22) | 10 (-8–16) | 0.318++ | 14.5 (9–21.5) | 8 (7–13) | 0.046++ | |
| Duration of postoperative hospital stay (days), r‡ | 0.26 | 0.034 | 0.17 | 0.173 | 7.5 (3.8) | 8.1 (5.3) | 0.618+ | 7.5 (3.5) | 8.9 (7.3) | 0.300+ | |
| Gynecological oncologist | No | 3 (2–5) | 0.057++ | 2 (2–4) | 0.182++ | 16 (53.3) | 14 (46.7) | 0.834‡ | 24 (80.0) | 6 (20.0) | 0.882‡ |
| Yes | 4 (3–6) | 3 (2–4) | 24 (55.8) | 19 (44.2) | 35 (81.4) | 8 (18.6) | |||||
| Urologist | No | 4 (2–5) | 0.207++ | 2 (2–4) | 0.083++ | 37 (55.2) | 30 (44.8) | 1.000‡‡ | 55 (82.1) | 12 (17.9) | 0.324‡‡ |
| Yes | 4.5 (3–6) | 4.5 (3–6) | 3 (50.0) | 3 (50.0) | 4 (66.7) | 2 (33.3) | |||||
| Type of anesthesia | Neuraxial | 3 (2–4) | 0.027++ | 2.5 (2–4) | 0.385++ | 16 (57.1) | 12 (42.9) | 0.750‡ | 25 (89.3) | 3 (10.7) | 0.147‡ |
| General | 4 (3–5) | 3 (2–4) | 24 (53.3) | 21 (46.7) | 34 (75.6) | 11 (24.4) | |||||
| Conversion to general anesthesia | No | 4 (2–5) | 0.444++ | 2 (2–4) | 0.511++ | 31 (59.6) | 21 (40.4) | 0.193‡ | 40 (76.9) | 12 (23.1) | 0.324‡‡ |
| Yes | 4 (2–4) | 3 (2–4) | 9 (42.9) | 12 (57.1) | 19 (90.5) | 2 (9.5) | |||||
| Admission to ICU | No | 4 (2–5) | 0.007++ | 2 (2–4) | 0.006++ | 38 (56.7) | 29 (43.3) | 0.321‡‡ | 57 (85.1) | 10 (14.9) | 0.018‡‡ |
| Yes | 6 (5.5–7.5) | 6 (4.5–7.5) | 1 (25.0) | 3 (75.0) | 1 (25.0) | 3 (75.0) | |||||
| Vasoactive drugs | No | 4 (2–5) | 0.044++ | 2.5 (2–4) | 0.049++ | 35 (58.3) | 25 (41.7) | 0.113‡ | 51 (85.0) | 9 (15.0) | 0.048‡‡ |
| Yes | 5 (3.5–6.5) | 5 (2–6) | 4 (33.3) | 8 (66.7) | 7 (58.3) | 5 (41.7) | |||||
| Invasive blood pressure monitoring | No | 2 (2–3) | 0.002++ | 2 (1–3) | 0.073++ | 5 (50.0) | 5 (50.0) | 0.741‡‡ | 8 (80.0) | 2 (20.0) | 1.000‡‡ |
| Yes | 4 (2.5–5) | 3 (2–4) | 34 (56.7) | 26 (43.3) | 49 (81.7) | 11 (18.3) | |||||
| Intravenous fluids administered | Colloids, r‡ | 0.20 | 0.092 | 0.20 | 0.096 | 0 (0–500) | 500 (0–500) | 0.230++ | 0 (0–00) | 500 (0–1,000) | 0.030++ |
| Crystalloids, r‡ | 0.30 | 0.011 | 0.14 | 0.261 | 3,769.2 (1,101.2) | 3,820.3 (1,324.6) | 0.860+ | 3,669.3 (1,177.9) | 4,292.9 (1,191.3) | 0.081+ | |
| APGAR score | First minute, r‡ | -0.08 | 0.506 | 0.13 | 0.292 | 7.5 (1.7) | 6.9 (2.5) | 0.301+ | 7.4 (1.8) | 6.7 (3.1) | 0.311+ |
| Fifth minute, r‡ | -0.01 | 0.947 | 0.21 | 0.170 | 8.1 (1.9) | 7.2 (3.1) | 0.247+ | 8 (2.1) | 6.7 (3.8) | 0.170+ | |